#### Title 1

2	Global solidarity in genomic surveillance improves early detection of			
3	respiratory virus threats			
4	Authors			
5	Simon P.J. de Jong <sup>1</sup> , Brooke E. Nichols <sup>2,3,4</sup> , Anniek de Ruijter <sup>5</sup> , Edyth Parker <sup>6</sup> , Vera			
6 7	Mitesser <sup>6</sup> , Christian Happi <sup>6</sup> , Menno D. de Jong <sup>1</sup> , Alvin X. Han <sup>1*</sup> , Colin A. Russell <sup>1*</sup>			
8	Affiliations			
9				
10	<sup>1</sup> Department of Medical Microbiology & Infection Prevention, Amsterdam University			
11	Medical Centers, University of Amsterdam, Amsterdam, The Netherlands			
12	<sup>2</sup> Amsterdam Institute for Global Health and Development, Department of Global Health,			
13	Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The			
14	Netherlands			
15	<sup>3</sup> Foundation for Innovative New Diagnostics (FIND), Geneva, Switzerland			
16	<sup>4</sup> Department of Global Health, Boston University, Boston, MA, USA			
17	<sup>5</sup> Law Centre for Health and Life, Faculty of Law, University of Amsterdam, Amsterdam, The			
18	Netherlands			
19	<sup>6</sup> African Centre of Excellence for Genomics and Infectious Diseases, Ede, Nigeria			
20				
21	*Contributed equally			
22				
23	Correspondence: <u>c.a.russell@amsterdamumc.nl</u>			

#### 25 Abstract

26 Public health decision-making for respiratory virus outbreaks relies heavily on genomic 27 sequencing to detect new (variant) viruses. However, respiratory virus sequencing infrastructure is highly unequally distributed globally, potentially limiting the efficiency and 28 effectiveness of surveillance efforts and raising concerns about preparedness for future threats. 29 Using mathematical models, we demonstrate that relative to global sequencing efforts during 30 31 the COVID-19 pandemic, increased global solidarity in respiratory virus genomic surveillance would vastly improve the capacity to rapidly detect novel threats, even with a substantially 32 33 reduced number of viruses sequenced globally, leading to improved effectiveness and efficiency. As a result, the time between a (variant) virus' first global detection and first local 34 35 case would increase in all countries, allowing for more time to design and implement global 36 and local public health measures to mitigate the threat's potential public health impacts. Our results show that operationalizing global health solidarity is key to guiding investment in 37 preparedness for future pandemic threats. 38

# Introduction 40

- 41 Genomic surveillance of respiratory viruses is a critical component of public health
- 42 preparedness and response, particularly for identifying and monitoring the spread of new
- viruses and their variants<sup>1-3</sup>. According to Article 5 of the International Health Regulations 43
- 44 (IHR), Member States to the World Health Organisation (WHO) are obligated to ensure
- 45 national surveillance capacity<sup>4</sup>. The COVID-19 pandemic represented the zenith of global
- respiratory virus sequencing output so far, with ~7 million SARS-CoV-2 genomes submitted 46
- 47 to GISAID (www.gisaid.org) in 2022 alone. However, this output was highly unequally
- 48 distributed<sup>5</sup>: half of all publicly shared genomes originated from countries that account for
- 49 only 4.4% of the global human population while half of the global population accounted for
- 50 only 0.7% of publicly shared genomes (Fig. 1a, Extended Data Fig. 1). Novel viruses and
- 51 their variants can potentially emerge in any country. As a result, the unequal distribution of
- 52 sequencing infrastructure potentially strongly limits the global capacity to rapidly detect
- 53 novel threats.
- 54 Early detection of (variant) viruses such as potential zoonotic reassortant influenza viruses or
- highly genetically divergent SARS-CoV-2 variants maximises the time available to 55
- 56 characterise the threat posed and design and implement potential interventions and mitigation
- strategies<sup>1,6–8</sup>. Hence, it is paramount for minimising potential public health impacts. To 57
- 58 guide efforts toward improved preparedness for future respiratory virus threats, it is important
- 59 to understand how the global landscape of genomic surveillance capabilities impacts the
- 60 ability to swiftly identify new respiratory viruses and their variants. Furthermore, planning
- towards enhanced preparedness requires meaningful minimum sequencing targets as well as 61
- 62 functional upper bounds for effective and efficient detection of new (variant) viruses<sup>2,3,5,9–11</sup>.
- We aimed to quantify how the global distribution of clinical genomic surveillance 63
- 64 infrastructure affects the global capacity to rapidly detect and characterize the spread of a
- novel respiratory virus (variant). First, we used a mathematical model to determine a target 65
- 66 minimum global sequencing capacity that balances effective performance and efficient
- resource use. Then, we leveraged large-scale epidemic simulations to investigate how 67
- 68 varyingly solidaristic global distributions of genomic surveillance infrastructure affect
- surveillance effectiveness. We used 2022 SARS-CoV-2 sequencing output as baseline, 69
- representing an empirical pandemic scenario with unprecedentedly high but highly unequally 70
- 71 distributed levels of virus genomic sequencing.

# **Results** 72

# 73 Global variation in pandemic-period detection capacity

- 74 To investigate how global variation in genomic surveillance capacity impacts the speed of
- new variant detection, we first investigated the performance of global genomic surveillance 75
- efforts for SARS-CoV-2 in 2022, representing an empirical baseline expectation for a 76
- 77 potential future pandemic scenario. Sequencing output in 2022 was highly unequally
- distributed: country-specific sequencing rates estimated from submissions to GISAID<sup>12</sup> 78
- 79 ranged from <0.01 sequences per million people per week (S/M/wk) in some countries to
- 80 >1000 S/M/wk in others (Fig. 1a). The median sequencing rate across European countries

- 81 amounted to 64.3 S/M/wk, compared to 0.18 S/M/wk for countries in Africa. Similarly, the
- 82 median time from sample collection to deposition in GISAID (henceforth, turnaround time)
- 83 ranged across countries from less than a week to hundreds of days (Fig. 1b).
- To understand how this variation impacts potential global detection capacity, we used a 84
- global metapopulation model, validated against GLEAM<sup>13,14</sup> (Extended Data Fig. 2), to 85
- 86 simulate hypothetical scenarios of global variant spread and subsequent detection. We
- 87 performed 10,000 independent simulations for values of variant  $R_e$  ranging from 1.2 to 2. We
- 88 assumed a distinct archetypal scenario of variant emergence, characterized by initial  $R_e$  and
- 89 prevalence of wildtype virus, for each value of variant  $R_e$  (Extended Data Fig. 3). In each
- simulation, the country where the variant emerged was randomly selected based on a country 90
- 91 population size-weighted probability. We then simulated the time to first variant detection for
- 92 each metapopulation epidemic simulation, given empirical country-specific SARS-CoV-2
- sequencing rates and turnaround times in 2022 (Fig. 1a,b). 93
- 94 Averaged across simulated variant  $R_e$  values, the mean time to first variant detection globally
- 95 was 83.0 days (95% CI 18 – 194), with substantial variability especially at lower values of
- 96 variant  $R_e$  (Fig. 1c). The simulated global number of variant infections by the day of first
- 97 global detection varied widely (mean 632,899 infections, 95% CI 77 – 5,917,647), spanning
- 98 up to five orders of magnitude for all values of variant  $R_e$  (Fig. 1d). In many simulations, new
- 99 variants were first detected outside of their continent of origin, driven especially by variants
- 100 first emerging in Africa (first detected outside origin continent in 75.0% of simulations), Asia
- 101 (23.5%) and South America (19.1%) (Fig. 1e). This means that the variant would have
- frequently spread widely within and between continents prior to initial detection (consistent 102
- 103 with, for example, the early spread and detection of the SARS-CoV-2 Omicron BA.1
- 104 variant<sup>1</sup>). The continent in which the variant first emerged strongly shaped the time to variant
- detection (Fig. 1f) and the number of global variant infections by the day of first detection 105
- 106 (Fig. 1g), the latter ranging from a mean of 23,006 infections (95% CI 29 – 242,943) when
- emerging in Europe to 1,757,677 infections (95% CI 1028 13,369,527) in case of 107
- emergence in Africa across simulated values of variant  $R_e$ . Differences in time to variant 108
- detection were strongly and highly nonlinearly associated with the sequencing capacity in the 109
- 110 country of origin of the novel virus, with low sequencing rates being associated with longer
- 111 times to variant detection (Fig. 1h).

# 112 **Operationalizing global health solidarity**

- Globally, there is a shared risk of the emergence of pandemic viruses or their variants. In 113
- 114 contrast, the results above indicate the capacity to rapidly detect new (variant) viruses is
- profoundly asymmetrically distributed. In part, this imbalance reflects a deficit of global 115
- 116 health solidarity. Solidarity as a principle specifically underlies institutionalized forms of
- sharing as a result of mutual dependence<sup>15,16</sup>; it gives guidance to human action in the face of 117
- interdependency related to the shared risks of communicable disease, and underlies the 118
- 119 obligations reflected in the IHR<sup>17,18</sup>. Given that pandemic risk is globally shared, we sought
- 120 to investigate how more or less solidaristic approaches to respiratory virus genomic
- 121 surveillance could lead to varyingly effective and efficient outcomes for purpose of the global
- 122 detection of novel (variant) respiratory viruses. To do so, we specifically considered national

- 123 respiratory virus genomic surveillance capacity. We first sought to identify a minimum
- 124 sequencing capacity at the national level that could serve as a target toward improving global
- capacity for rapid global (variant) virus detection. Ideally, this target would ensure timely 125
- information for public health action as well as efficient use of potentially limited resources. It 126
- 127 would also need to be realistically attainable and sustainable in pandemic and inter-pandemic
- 128 periods.
- 129 To identify a target minimum global sequencing capacity, we explored the relationship
- between sequencing rate, turnaround time, and time to variant detection in any single country 130
- 131 in more detail. Representing a scenario of emergence of a potential future pandemic
- respiratory virus (variant), we simulated the emergence of a variant virus in the background 132
- 133 of circulating wildtype virus and computed the expected time to variant detection based on
- 134 binomial sampling for different sequencing rates. We then derived a new mathematical model
- 135 characterising the relationship between sequencing rates and time to detection of the new
- 136 virus variant. For a variant virus, introduced in a population at an initial frequency  $f_0$ , where
- the change in variant proportion through time can be described by a logistic growth rate s, the 137
- 138 time since variant introduction when the variant virus is expected to have been detected with
- 139 confidence level 1-q when sequencing *n* samples per unit time is equal to
- 140  $(\log[(q^{-s/n}-1)/f_0]+1)/s$  (Extended Data Fig. 4). This model is applicable to all respiratory
- viruses that can be described by SIR dynamics<sup>19</sup>, including SARS-CoV-2, seasonal influenza 141
- 142 virus, respiratory syncytial virus, and potential future pandemic respiratory viruses.

# 143 Benefits of increases in sequencing rate are rapidly diminishing

- 144 For all modelled scenarios of variant emergence (Extended Data Fig. 3), time to variant detection rapidly decreased as sequencing rate increased up to  $\sim 10$  S/M/wk while the benefits 145
- of increases in sequencing rate beyond 10 S/M/wk were much smaller (Fig. 2a, Extended 146
- 147 Data Fig. 5a). In 2022, many high-income countries sequenced SARS-CoV-2 genomes at
- rates well in excess of 10 S/M/wk, whereas sequencing rates in many lower-and-middle-148
- 149 income countries were such that, in absolute terms, small increases would substantially speed
- 150 up variant detection (Fig. 2a, Extended Data Fig. 5a). For example, in a country of 100
- 151 million people sequencing at the median 2022 SARS-CoV-2 sequencing rate in low-income
- 152 countries (0.035 S/M/wk), increasing the sequencing rate by 1 S/M/wk would reduce the time
- to detection of a variant with  $R_e = 1.6$  at 95% confidence by ~28 days, given a wildtype 153
- 154 prevalence of 0.5% and a wildtype  $R_e$  of 1.1 at time of variant emergence. In contrast, if the
- 155 same country was sequencing at the 2022 median high-income country rate (58.9 S/M/wk),
- the reduction in time to detection resulting from the same 1 S/M/wk increase in sequencing 156
- 157 rate would be only 3.5 hours (Fig. 2a, Extended Data Fig. 5b). The diminishing returns at rates characteristic of high-income countries are particularly prominent when looking at the 158
- 159 relationship between sequencing rate and the expected number of variant infections by the
- 160 day the variant has been detected (Fig. 2b, Extended Data Fig. 6a). Assuming a 14-day
- 161 turnaround time, increasing the sequencing rate in a country sequencing at the median low-
- income country rate by 1 S/M/wk would reduce the expected number of variant infections by 162
- the time of detection with 95% confidence by ~4.5 million infections for the scenario of 163
- 164 variant emergence described above; in a country sequencing at the median high-income rate,

- 165 the same 1 S/M/wk increase would only reduce the expected number of variant infections by 166 the day of first detection by ~60 infections (Fig. 2b, Extended Data Fig. 6b).
- 167 In addition to sequencing rate, turnaround time is an essential component of effective
- genomic surveillance<sup>2,5,20,21</sup>. For reducing time to variant detection, any reduction in 168
- turnaround time is functionally equivalent to a fold increase in sequencing rate (Fig. 2c). 169
- 170 Reductions in turnaround time are especially valuable for the detection of variant viruses that
- 171 are highly transmissible. For example, for the archetypal variant with  $R_e = 2$ , a three-week
- 172 reduction in turnaround time is equivalent to an 89.0-fold increase in sequencing rate (Fig.
- 173 2c). Hence, the benefits of increasing sequencing output should be carefully weighed against
- 174 the gains from strengthening the ancillary infrastructure necessary for timely availability of
- 175 sequencing results.
- Using these results, we identified a possible target for a global minimum sequencing 176
- 177 capacity. Given the identified relationship between sequencing rate, turnaround time, and
- time to detection, a sequencing capacity of 2 S/M/wk with a two-week turnaround time is a 178
- 179 sensible potential global minimum target (Fig. 2a, vertical grey line). Its position at the elbow
- 180 of the relationship between sequencing rate and time to detection (Fig. 2a) suggests that 2
- S/M/wk is efficient, and its rapid variant detection even when a highly transmissible variant 181
- emerges in the background of high wildtype prevalence suggests that it results in strong 182
- 183 performance. We chose a relatively low turnaround time of fourteen days given the vital
- 184 importance of turnaround time in shaping time to detection. A sequencing rate of 2 S/M/wk
- 185 corresponds to 0.18% of the maximum country-specific SARS-CoV-2 sequencing rate in
- 186 2022. If all countries sequencing at rates lower than 2 S/M/wk in 2022 were to attain this
- minimum capacity, the *de novo* generated sequencing capacity would represent 6.0% of 187
- 188 global sequencing output in 2022. This suggests that in terms of raw sequencing capacity, the
- 189 expansion necessary to effectuate the global minimum would be modest compared to
- 190 empirical global sequencing output in a pandemic scenario.

### 191 Global solidarity improves surveillance effectiveness and efficiency

- 192 To model the effect of more solidaristic global genomic surveillance, we re-simulated the
- 193 global (variant) virus detection process given the global metapopulation epidemic simulations
- 194 in a scenario where all countries possessed a global minimum capacity of at least 2 S/M/wk
- 195 with 14-day turnaround time. Ensuring this global minimum sequencing capacity globally
- 196 while keeping sequencing output unchanged for countries that already satisfied the minimum
- 197 requirement in 2022 (henceforth, strategy A) reduced mean time to global variant detection
- 198 by 26.0 days to 57.0 days (95% CI 17 - 119) relative to the simulated 2022 baseline (red bar,
- 199 Fig. 3a). The mean number of global variant infections by the day of detection decreased
- 200 from 632,899 infections (95% CI 77 – 5,917,647) to 31,485 infections (95% CI 67 – 235,057)
- 201 (red bar, Fig. 3b), and the probability that the variant was first detected in its origin continent
- 202 increased from 71.0% to 96.4% (red cross, Fig. 3c).
- 203 Since reductions in time to detection resulting from increases in sequencing rate beyond  $\sim 10$
- 204 S/M/wk (Fig. 2b) are limited, we further hypothesized that relative to the 2022 baseline,
- 205 limiting sequencing rates to 30 S/M/wk would have little detrimental effect on time to variant
- 206 detection (Fig. 2a, vertical grey line). In our simulations, setting a 30 S/M/wk upper limit in

207 all countries relative to the 2022 baseline but no minimum requirement (henceforth, strategy 208 B) left the expected time to first global variant detection (green bar, Fig. 3a) and the expected number of variant infections by the day of detection (green bar, Fig. 3b) largely unchanged: 209 210 mean time to variant detection increased by only 4.6 days, from mean 83.0 days to 87.6 days

(95% CI 22-202) (green bar, Fig. 3a), while global sequencing output was reduced by 67.0%. 211

212 To model a globally solidaristic approach to respiratory virus genomic surveillance, we

213 combined the insights that establishing a global minimum sequencing capacity could strongly 214 reduce time to variant detection whereas the reductions in time to detection beyond  $\sim 10$ 

- 215 S/M/wk rapidly diminish. Simulations indicated that in a hypothetical future pandemic
- scenario, ensuring a minimum global capacity of 2 S/M/wk, while also setting a 30 S/M/wk 216
- 217 upper limit (henceforth, strategy C), could improve time to variant detection by weeks while
- 218 still reducing sequencing output by 61.0% relative to the 2022 pandemic baseline (blue bar,
- 219 Fig. 3a, Extended Data Fig. 7). This result suggests that achieving a global minimum
- 220 surveillance capacity could allow for substantial improvements in the capacity for rapid
- global virus detection, even with substantially fewer total viruses sequenced globally. We 221
- 222 also investigated a scenario of independent country-level expansion, where each country's
- sequencing output increased proportional to its existing rate. Independently doubling each 223
- 224 country's 2022 sequencing output, (strategy D) would only reduce mean time to detection by
- 7.2 days (brown bar, Fig. 3a, Extended Data Fig. 7), suggesting that siloed expansion of 225

226 individual countries' sequencing output cannot replace a solidaristic global approach.

- 227 Initial detection is a necessary starting point for responses to potential novel threats.
- 228 However, additional information beyond simple detection is often necessary to characterize
- 229 the public health risk that a (variant) virus poses. For example, the SARS-CoV-2 Alpha
- variant was first detected in the UK in a sample collected on 20 September 2020, likely 230
- within days of its initial emergence<sup>22</sup>. However, it was not until December 2020 that 231
- epidemiological evidence of the variant's transmission advantage relative to pre-existing 232
- viruses began to accumulate<sup>22,23</sup>. To that end, we also investigated how a more solidaristic 233 234 global distribution of sequencing output would affect the time elapsed until the variant would
- have been estimated to account for a substantial proportion of circulating virus, suggestive of 235
- 236 a potential transmission advantage. In our simulations, the time until estimated variant
- 237 frequencies, in at least one country, provided evidence with 95% confidence that the variant
- had reached 1% circulating frequency, decreased from 117.7 days (95% CI 42-252) for the 238
- 239 2022 baseline to 103.8 days (95% CI 42-210) for strategy C (Extended Data Fig. 8a).
- Correspondingly, the mean number of global infections by that day decreased from 2,072,633 240
- 241 (95% CI 4,896-20,293,166) to 205,311 (95% CI 4,873-1,428,529) (Extended Data Fig. 8b).
- 242 In contrast, capping sequencing rates at 30 S/M/wk (strategy B) increased the mean time until
- the variant was established to have reached 1% circulating frequency somewhere globally by 243
- 244 only 0.5 days relative to the 2022 baseline (Extended Data Fig. 8a). Mathematical models
- 245 indicate that a sequencing capacity of 2 S/M/wk would ensure robust ascertainment of variant
- prevalence (Extended Data Fig. 9). 246

# 247 Solidaristic approaches improve opportunities for mitigation

248 To investigate how establishing a global minimum capacity could affect public health

- 249 preparedness, we computed the mean lead time between first global detection and the first
- 250 local case for all countries under the different strategies. As the first global detection of a
- 251 (variant) virus represents a potential starting point for the design and implementation of local
- 252 public health responses, this lead time provides a measure for individual countries of the time
- 253 horizon for public health measures that aim to mitigate potential impacts. In all countries, the 254 lead time would increase under more solidaristic distributions of global sequencing
- 255 infrastructure (Fig. 3d), potentially allowing for more time to implement public health
- 256 measures in preparation for variant outbreaks or nascent pandemics. For example, for the
- 257 archetypal variant virus with  $R_e = 1.6$ , the mean time between first global detection and
- 258 arrival in the United States was -8.5 days under the 2022 baseline, suggesting that on average,
- 259 the variant would already be present in the United States by the time it was first detected
- 260 globally. Under the solidaristic strategy C, the public health lead time in the US increased by
- two weeks to +6.6 days. The increases in lead time were stronger for lower values of  $R_e$ ; for 261
- example, for the archetypal variant with  $R_e = 1.3$ , the mean lead time increased from +114 to 262
- +144 days in Rwanda, +82 to +111 days in Kazakhstan, +47 to +76 days in Indonesia, and 263
- 264 +21 to +51 days in the United Kingdom, for strategy C relative to the 2022 baseline.

# Discussion 265

- 266 Our results indicate that operationalizing global health solidarity in respiratory virus genomic
- surveillance could strongly improve preparedness for potential future respiratory virus 267
- 268 threats. Relative to siloed surveillance efforts, where countries' policies are strongly
- domestically focused, pursuing sustainable global capacity could substantially reduce the 269
- 270 time to first global detection of variant viruses and the time until variant viruses are found to
- 271 exhibit signatures of rapid spread. Initial detection and sequencing is a necessary first step in
- assessing and responding to the threat posed by novel viruses and underlies the design and 272
- 273 deployment of countermeasures such as vaccines and therapeutics<sup>7,24</sup>. As such, earlier
- 274 warning of potential threats could substantially improve the time horizon for global and local
- 275 public health measures that aim to mitigate viral threats' potential impacts, and solidaristic
- approaches to global genomic surveillance could improve outbreak preparedness and 276
- 277 response for all countries globally.
- 278 Our results suggest that only a small fraction of pandemic-period sequencing output, in the 279 right places, could transform the global capacity to rapidly detect novel threats. This fact, 280 combined with the fact that a country can only detect a virus that emerged elsewhere once it 281 is already present locally, suggests that to improve outbreak preparedness, siloed expansion 282 of surveillance capacity in countries that already possess strong capacity cannot replace solidaristic global investment, and that solidaristic approaches to genomic surveillance could 283 284 yield greater public health benefit even to countries that already possess strong surveillance 285 infrastructure locally. Our analyses are primarily focused on detecting novel (variant) viruses and tracking their spread. Hence, our arguments weighing the enhancement of local 286 surveillance capacity against the development of basic global capacity do not consider 287 288 ancillary benefits of high-intensity genomic surveillance in high-income settings such as 289 characterization of local transmission dynamics. However, we stress the fundamental

- 290 immediate importance of basic global capacity for initial detection for all countries, such as
- in the context of vaccine development and deployment, where speed-ups of a few weeks
- 292 could have substantial public health impacts globally<sup>25</sup>.
- 293 In our model we assumed representative sampling in the genomic surveillance process,
- including the ready availability and access to diagnostic tools, which does not always hold in
- reality<sup>26,27</sup>. As the departure from this assumption is especially strong in resource-constrained
- settings $^{20,26}$ , the reported reductions in time to variant detection resulting from the
- 297 establishment of a global minimum sequencing capacity are likely underestimates.
- 298 Furthermore, our model does not model the spatial distribution of the minimum capacity in
- the country. The spatial distribution of sequencing capacity and the structure of sample
- 300 referral networks interplays with turnaround time to shape surveillance performance and
- 301 affects the optimal country-level implementation of surveillance networks. Our model is not
- 302 applicable to (variant) viruses with no or a detrimental effect on transmissibility such as those
- that only result in increased disease severity or reduced sensitivity of diagnostics.
- 304 Importantly, our results are robust to biases in the estimates of turnaround time resulting from
- delays in sequence deposition in GISAID<sup>28,29</sup> (Extended Data Fig. 10a) and deviations from
- 306 the assumed global mobility rates (Extended Data Fig. 10b).
- 307 While solidarity is a helpful principle to guide policy in the case of an interdependence of
- 308 risks given a particular context, reaching health equity or health justice will require
- 309 overcoming substantial challenges<sup>30–35</sup>. Even with the capacity to detect new viruses sooner,
- 310 the capacity to respond is also distributed asymmetrically. Even if the proposed models help
- 311 undergird global health solidarity, the benefits of more rapidly available vaccines or better-
- 312 matched vaccine updates due to timelier detection will only extend to countries with access to
- these benefits<sup>30–32,36</sup>. Furthermore, rapidly detecting and sharing information concerning new
- 314 (variant) viruses must not paradoxically disadvantage countries that do so. Open sharing of
- 315 pathogen genomic data must operate within a system of fair access and benefit-sharing to
- achieve its intended public health purpose without exacerbating global health inequity 33,36,37.
- 317 Despite these challenges, in many countries there is a desire for enhanced genomic
- 318 surveillance capacity to inform local public health responses 21,27,29,38,39.
- 319 Given the relationship between turnaround time and sequencing rate, we proposed a
- 320 sequencing capacity of 2 S/M/wk with 14-day turnaround time as a target. We note that given
- 321 this capacity, the optimal sequencing rate and its balance with turnaround time depends on
- 322 the characteristics of the pathogen, the epidemiological background in which the variant were
- 323 to emerge, and the required timeliness of sequencing data for public health action; for
- 324 example, when levels of wildtype respiratory virus circulation are very low, relatively fewer
- 325 sequences might yield a better balance between surveillance performance and resource use.
- 326 The proposed target aims to balance the resources necessary for surveillance in periods of
- 327 seasonal circulation of respiratory pathogens with the capacity to rapidly detect and scale up
- 328 capacity during potential pandemic scenarios. While our study is focused on respiratory
- 329 viruses and their variants, leveraging the infrastructure associated with the proposed target for
- 330 surveillance of non-respiratory pathogens would yield further benefits. Our results underscore
- the importance of turnaround time in shaping the effectiveness and public health utility of

- 332 surveillance efforts<sup>20,21</sup>, and particularly its balance with sequencing rate. Relieving barriers
- to attaining low turnaround times in resource-limited settings, such as the availability of
- reagents, is key to realizing the potential benefits of global surveillance capacity<sup>20,40</sup>.
- 335 While our modelling results provide a principled target that balances resource use and
- performance, the optimal design, including the balance of sequencing rate and turnaround
- time, will likely differ from country to country, depending on local constraints and priorities.
- 338 Our study provides quantitative evidence of how solidaristic approaches provide a rational
- 339 basis for improving global surveillance performance, but implementation requires addressing
- 340 challenges related to infrastructure, personnel, and funding that currently form barriers to the
- 341 implementation of genomic capacity in under-resourced settings<sup>29,40–42</sup>. To achieve the long-
- 342 term advancement of global genomics capacity in these settings, coherent capacity-building is
- 343 necessary, and that requires sustainable, diversified financing which minimizes dependency
- on single funding source while aligning well with national needs<sup>40</sup>.
- 345 The COVID-19 led to an unprecedented expansion of sequencing capacity globally. Some of
- 346 the most consequential gains were made in resource-limited settings $^{20,21}$ , and it essential that
- 347 such gains are maintained and where necessary expanded to maximize preparedness for
- 348 future threats. Our results suggest that a global minimum respiratory virus sequencing
- 349 capacity offers a path toward improved responses to respiratory virus threats, even for
- 350 countries with existing strong national surveillance capacities. For these countries, supporting
- a global minimum sequencing capacity could yield benefits in preparation for and during
- 352 potential future outbreak scenarios that are not attainable through siloed focuses on local
- 353 capacity. Our study shows how a global outlook on pandemic preparedness is essential to
- 354 improve both global and local public health. To improve outbreak preparedness, there is no
- 355 substitute for global solidarity; it offers a path toward better responses to respiratory virus
- threats that would be mutually beneficial to all WHO Member States.
- 357





Figure 1. The global time to variant detection based on the SARS-CoV-2 genomic
 sequencing landscape in 2022.

364 (A) Distribution of non-zero country-specific weekly sequencing rates per million people by continent estimated from GISAID metadata (N = 199) (AF: Africa, EU: Europe, OC: 365 Oceania, AS: Asia, NA: North America, SA: South America). (B) Distribution of median 366 country-specific time from sample collection to sequence deposition in GISAID, i.e. 367 turnaround time (N = 199). (C) The distribution of days to variant detection for different 368 values of variant  $R_e$  in global metapopulation model simulations, each with a distinct scenario 369 of variant emergence (N = 10,000 for each variant  $R_e$ ). Vertical lines correspond to the 370 median and 95% CI. (**D**) The simulated distribution of the number of global variant infections 371 372 by the day of first variant detection. (E) The simulated probability that the variant is first 373 detected in its origin continent, by origin continent. (F) The simulated time to variant 374 detection by variant origin continent. Thin and thick lines correspond to 95% and 50% CIs, 375 respectively. Points correspond to means. (G) The simulated number of global variant 376 infections by the day of detection by variant origin continent, analogous to F. (H) The relationship between a country's sequencing rate and the mean time to first global detection 377 of a variant emerging in that country in metapopulation simulations (N = 160 for each variant 378  $R_e$ ). Lines correspond to LOESS fits by variant  $R_e$ . 379 380



381



### turnaround time for a single country. 383

(A) Relationship between sequencing rate and the number of days until the variant will have 384

been detected with 95% confidence. The small black tick marks on the x-axes in this plot and 385

386 in B show country-specific SARS-CoV-2 sequencing rates for 2022. Vertical dotted lines

correspond to the median SARS-CoV-2 sequencing rates for high-income (HIC) and low-387

income (LIC) countries in 2022. In all panels, lines are coloured by values of variant  $R_{e}$ , with 388

a distinct scenario of variant emergence for each value of variant  $R_{\rm e}$ ; sequencing turnaround 389 time was assumed to be 14 days. (B) Relationship between sequencing rate and the expected 390

391 number of variant infections by the day the variant will have been detected with 95%

392 confidence. (C) Relationship between a reduction in turnaround time (in days) and the fold

increase in sequencing rate that would be required to effect the same reduction in time to 393

- 394 detection if turnaround time was kept constant.
- 395





396

#### Figure 3. The time to first global detection of a new variant under varying global 397 398 distributions of global respiratory virus genomic surveillance infrastructure.

399 (A) Comparison of time to variant detection for different global strategies for the global distribution of genomic surveillance infrastructure. Each value of variant  $R_e$  corresponds to a 400 401 distinct scenario of variant emergence (N = 10,000 for each). Thin and thick lines correspond to 95% and 50% CIs, respectively. Points correspond to means. (B) The cumulative number 402 403 of global variant infections by the day of variant detection by strategy, analogous to A. (C) The probability that the variant is first detected in its origin continent, by strategy. (D) 404 Comparison of the mean time between the first detection of the variant globally, and the first 405 406 local within-country infection, by strategy, for individual countries, averaged across values of variant  $R_e$  (N = 195 for each strategy). Each point corresponds to a country, coloured by 407 continent (AF: Africa, EU: Europe, OC: Oceania, AS: Asia, NA: North America, SA: South 408 409 America). Boxplots show the median, first and third quartiles, and minimum and maximum 410 values.

- 411
- 412

#### 413 **Methods**

414

### 415 *Operationalizing global health solidarity*

416

417 Genomic surveillance capacity has become a core component of preparedness and response to 418 global disease outbreaks. In accordance with Article 5 and annex 1 of the International Health 419 Regulations (IHR), Member States of the World Health Organization (WHO) must ensure 420 national surveillance capacity. The WHO can assist Member States to develop, strengthen and 421 maintain surveillance capacities as needed (Article 5(4) IHR)<sup>4</sup>. Underlying this obligation is 422 solidarity; a principle that gives guidance to human action in the face of interdependency 423 because of the shared risks of communicable disease<sup>17,18</sup>.

424

425 Solidarity connotes a sense of commitment to help similar others in need<sup>43</sup>. More specifically 426 solidarity – quite apart from charity or other forms of 'helping out' and sharing – as a principle 427 underlies institutionalized forms of sharing as a result of mutual dependence<sup>15,16</sup>. Solidarity is

relational, meaning that its institutional scope is determined by societal bounds of whom we 428

- 429 feel solidary towards<sup>44,45</sup>. In the field of health this plays out in national schemes of health insurance, redistribution, planning and rationing to ensure access to medicines and services<sup>46,47</sup>. 430
- 431

432 The relational aspect of solidarity has made it difficult globally to determine what exactly is owed in interstate and global health interactions. In this regard it has been argued that in global 433 434 health, solidarity needs to be based on 'similarity in a *specific context*'<sup>43</sup>. In line with this 435 presupposition, we operationalize global health solidarity here specifically considering national 436 capacity for genomic sequencing, by modelling for the most effective and efficient global 437 distribution to the extent that we globally face the shared risk of unforeseeable pandemic 438 respiratory virus occurrence. Operationalizing global health solidarity through modelling the 439 global distribution of genomic sequencing capacity in this regard can guide WHO efforts to the 440 implementation of Article 5 IHR, and to rationally invest in genomic sequencing capacity 441 where needed to safeguard global pandemic preparedness as risk-sharing among WHO's Member States. 442

443

444 *Sequence metadata analysis* 

445

We downloaded metadata corresponding to all SARS-CoV-2 genomes in the GISAID<sup>12</sup> 446 447 database with collection date from January 1st to December 31st 2022 and submission date 448 before July 1<sup>st</sup> 2023 (n = 6,914,601). For each country with at least one sequence in the 449 dataset, we computed the weekly sequencing rate by dividing the number of viruses sampled 450 in that country by 52 and the country's population size in millions, yielding a sequencing rate 451 in units of sequences per million people per week (S/M/wk). Population sizes for July 1st 452 2022 were extracted from the United Nations World Population Prospects 2022 453 (https://population.un.org/wpp/Download/Standard/MostUsed/). For each sequence, we 454 computed the turnaround time from the number of days between the sample collection and 455 submission day in GISAID. We extracted countries' per capita gross domestic product

456 (GDP) for 2022, or the most recent year before 2022 if data for 2022 was unavailable, from

457 the World Bank (https://data.worldbank.org/indicator/NY.GDP.PCAP.CD (last updated 458 2023/10/26)). We extracted income classifications for each country for fiscal year 2024 from 459 the World Bank (https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-

- bank-country-and-lending-groups). 460
- 461
- 462 Variant epidemic simulations
- 463

464 In all analyses, we assumed that a variant virus emerges in the context of circulating wildtype 465 virus. In our simulations, both variant and wildtype epidemiological dynamics are described by a susceptible-infected-recovered (SIR) compartmental model with infectious period  $1/\gamma$ 466 equal to 5 days for both viruses, with no interactions between genotypes. We simulated 467 variant epidemics under a range of values of variant  $R_e$  at time of introduction (variant  $R_e$  = 468 469 1.2, 1.3, 1.6, and 2). In the main text, we assumed a different scenario of variant emergence for each value of variant  $R_e$ , characterized by a wildtype (wt)  $R_e$  at time of variant 470 introduction and a wildtype prevalence at time of variant introduction (variant  $R_e = 1.2$ : wt  $R_e$ 471 472 = 1, wt prevalence = 0.1%; variant  $R_e = 1.3$ : wt  $R_e = 1.05$ , wt prevalence = 0.2%; variant  $R_e =$ 1.6: wt  $R_e = 1.1$ , wt prevalence = 0.5%; variant  $R_e = 2$ : wt  $R_e = 1$ , wt prevalence = 2%). These 473 474 scenarios were chosen such that circulation dynamics of wildtype and variant were 475 comparable (e.g. the emergence of a highly transmissible variant in the background of high wildtype prevalence). In the Extended Data Figures, we show the same analyses for all 476 477 combinations of variant  $R_e$  and scenario of variant emergence (e.g. a variant with  $R_e = 2$  with wildtype dynamics corresponding to the scenario for variant  $R_e = 1.2$  (wt  $R_e = 1$ , wt 478 479 prevalence = 0.1%)). Epidemic dynamics for each scenario in the main text are shown in Extended Data Fig. 3. While we report results based on variant  $R_e$ , we note that results are 480 primarily dependent on the logistic growth rate of the variant proportion (see section 481 482 'Mathematical model' below). In this context, the scenario of variant  $R_e = 2$  with wt  $R_e = 1$  is, 483 for example, functionally equivalent to a scenario with variant  $R_e = 2.5$  and wt  $R_e = 1.5$ . Similarly, the first scenario of variant  $R_e = 1.2$  and wt  $R_e = 1$  is functionally equivalent to a 484 485 scenario of variant  $R_e = 1.6$  and wt  $R_e = 1.3$ , approximating a scenario of emergence of a 486 A/H1N1pdm09 pandemic-like virus early in a seasonal influenza virus epidemic.

487

488 *Metapopulation model* 

489

490 We used a metapopulation model that couples local SIR dynamics within each index country 491 with global migration to simulate the global spread of a variant. Given a rate of movement 492  $w_{nm}$  from population m to n, the expected number of variant-infected  $(I_n)$  and variant-493 susceptible  $(S_n)$  people in population n with population size  $N_n$  for a variant with 494 transmission rate  $\beta$  and recovery rate  $\gamma$ , is described by

496 
$$\partial_t I_n = \frac{\beta S_n I_n}{N_n} - \gamma I_n + \sum_{m \neq n} (w_{nm} I_m - w_{mn} I_n)$$

497 
$$\partial_t S_n = \frac{-\beta S_n I_n}{N_n} + \sum_{m \neq n} (w_{nm} S_m - w_{mn} S_n)$$

# 498

- 499 This model is the basis of the model used by Brockmann et al.<sup>48</sup> to fit empirical arrival times for multiple respiratory viruses to global air transportation data. We used the estimated 500 pairwise number of trips between all countries from the Global Transnational Mobility 501  $(GTM)^{49}$  to inform  $w_{nm}$ . This dataset combines a tourism dataset from the World Tourism 502 503 Organization and an origin-final destination dataset corresponding to global air travel data. Previous work has validated the GTM against the world airline network<sup>50</sup>, which Brockmann 504 et al. <sup>48</sup> showed to strongly reproduce observed dynamics of global pathogen spread. 505 Specifically, for any two countries *n* and *m* we computed  $w_{nm}$  by dividing the number of trips 506 from country *m* to *n* in the year 2016 by the population size of country *m* and by 365. For 507 508 each value of variant  $R_{e}$ , we performed 10,000 independent simulations of the 509 metapopulation model, assuming that the probability a variant virus would emerge in a 510 particular country is proportional to the country's relative population size (simulations 511 initialized in Africa: n = 1793; Asia: n = 5946, Europe: n = 934; North America: n = 739; Oceania: n = 54; South America: n = 534). We integrated the model forward in time at a daily 512 513 timescale using a tau-leap algorithm, which also furnishes the epidemic dynamics and global spread with stochasticity. Each simulation was initialized with an infected population of 10 514 515 individuals. 516 We validated the metapopulation model by comparing arrival times against those that were 517 independently estimated using GLEAM<sup>14</sup>, a separate metapopulation model that incorporates 518 commuting but which relies on different underlying data. Given an epidemic origin location, 519
- 520 we simulated 10 epidemic instances using the metapopulation model, each initialized with 10
- 521 infected individuals, and we simulated 10 instances using GLEAM, where we implemented
- 522 the same SIR model. In the GLEAM simulations, we assumed 100% of airline traffic, no
- 523 seasonality, and a gravity commuting model with 8 hours spent at the commuting
- 524 destinations. For each country, we computed the first day on which median cumulative incidence across simulations exceeded 0.01 per 1000 individuals for both model
- 525 526 implementations. We performed these simulations for ten countries (Cameroon, Ecuador,
- 527 France, Jamaica, Malaysia, Mali, Nepal, Nicaragua, Oman, Uzbekistan) with the GLEAM
- 528 model initialized in each country's capital city. For all ten origin locations we find a strong
- 529 concordance between arrival times (r = 0.89 overall) estimated using the metapopulation
- 530 model and GLEAM (Extended Data Fig. 2). This provides support for the use of the
- 531 metapopulation model.
- 532
- 533 Global genomic surveillance simulations
- 534

535 We performed the genomic surveillance simulations using empirical turnaround times and 536 sampling rates for each country, using data for 2022. For each sequence in GISAID, we

537 computed the time T between the sample's collection date and submission date. For each

country c, the turnaround-time specific sequencing rate in unit of sequences per day  $n_{x,c}$ , for 538

- each value of turnaround time x in days, was equal to the country's total sequencing rate in 539
- 540 sequences per day multiplied by the proportion of sequences from that country with T = x.
- 541

542 For each country in each simulation, starting from the first day on which the number of new 543 variant infections exceeded 10 onwards, we deterministically simulated the wildtype

543 variant infections exceeded 10 onwards, we deterministically simulated the wildtype 544 epidemic dynamics. For each value of variant  $R_e$ , we assumed a scenario of variant

epidemic dynamics. For each value of variant  $R_{e}$ , we assumed a scenario of variant semergence (characterized by a wildtype prevalence and wildtype  $R_{e}$ ) as described above in

546 the main text. In the Extended Data Figures, we show the same analyses for all combinations

of variant  $R_e$  and scenario of variant emergence. Until the first day on which the number of

548 variant infections exceeded 10, wildtype incidence was assumed to be equal to wildtype

549 incidence on the first day of the simulated wildtype epidemic, to account for the stochasticity

observed when the number of infections was small and the potential for stochastic variant

551 extinction.

552

553 Using the simulated variant and wildtype incidence on each day, we computed the variant

554 proportion through time f(t). For each country c, on each day t, we used the simulated

555 country-specific variant proportion  $f_c(t)$  to simulate genomic surveillance: For each value of

turnaround time x, we assumed that total sample count  $\tilde{n}_{x,c} \sim \text{Poisson}(n_{x,c})$  and simulated the

557 total number of variant samples  $V_c(t) = \sum_{x=0}^t v_{x,c}$ , with  $v_{x,c} \sim \text{Binomial}(\tilde{n}_{x,c}, f_c(t-x))$ . In each

of 10,000 replicate simulations, and for each strategy for the global distribution of

- 559 surveillance infrastructure (see next section), we computed the detection day as the first day t560 on which  $V_c(t)$  was at least one in at least one country c. We defined the detection country as
- the first country for which this held.
- 562

To investigate the time until the variant could be said to account for a substantial proportion 563 of circulating virus in at least one country, we used the simulated weekly sequence counts to 564 565 compute, for each country, if there was any week in the past in which the variant accounted for at least a proportion  $\pi$  of all samples collected that week with 95% confidence given a 566 one-tailed binomial test for proportions. We performed this analysis on a weekly basis for 567 each country, and the day on which the *p*-value for this binomial test declined below 0.05 in 568 at least country, for any week in the past, was defined as the day the variant was established 569 570 to account for a substantial proportion of circulating virus in at least one country globally. We 571 chose  $\pi$  to be 1% for all countries with a population of 100 million individuals or fewer. We ensured a more flexible threshold for countries with a population larger than 100 million. For 572 573 these countries, the threshold decreased proportionally as the population size increased, e.g. 574 using a threshold of 0.5% for a population of 200 million individuals and a threshold of 0.1% 575 in a population of 1 billion individuals.

576

577 Global surveillance strategies

578

579 We investigated five strategies for the global distribution of sequencing infrastructure:

580

581 Strategy 2022: the 2022 baseline. For each country, turnaround time-specific sequencing

582 rates were extracted from GISAID metadata.

584	Strategy A: the 2022 baseline + a global minimum sequencing capacity of 2 S/M/wk with 14-
585	day turnaround time in each country. If a country already satisfied this requirement (i.e., the
586	sum of turnaround time-specific sequencing rates with turnaround time $\leq 14$ days was equal to
587	or greater than 2 S/M/wk), its sequencing rates were unchanged relative to the 2022 baseline.
588	If a country satisfied the sequencing rate across all values of turnaround time, but not within
589	the required two-week turnaround time, the deficit in S/M/wk in the sum of turnaround time-
590	specific sequencing rates with turnaround time $\leq 14$ days was uniformly removed from the
591	sequencing rates exceeding 14 days and added to the sequencing rate corresponding to a
592	turnaround time of 14 days. Hence, in this scenario, total sequencing output remained
593	unchanged, and the minimum sequencing capacity was attained by reducing turnaround time.
594	If a country did not satisfy the minimum sequencing rate at all, all sequencing output
595	corresponding to a sequencing rate >14 days was set to a turnaround time of 14 days. The
596	remaining deficit in S/M/wk in the sum of turnaround time-specific sequencing rates with
597	turnaround time $\leq 14$ days was added to the sequencing rate corresponding to a turnaround
598	time of 14 days.
599	
600	Strategy B: Equivalent to the 2022 baseline, but individual countries' sequencing output
601	capped at 30 S/M/wk. Countries that sequenced at rates exceeding 30 S/M/wk had their
602	sequencing output capped by dividing sequencing rate uniformly across all values of
603	turnaround time such that total output across all values of turnaround time was equal to 30
604	S/M/wk.
605	
606	Strategy C: A combination of strategies A and B. In countries that, after capping according to
607	strategy B, did not satisfy the minimum sequencing rate of 2 S/M/wk with 14-day turnaround
608	time, this minimum was ensured analogous to Strategy A.
609	
610	Strategy D: The 2022 baseline, doubled. In each country, the sequencing rate in 2022 was
611	doubled across all values of turnaround time. Hence, the absolute increase in sequencing
612	output was greater in countries that had a higher baseline sequencing rate.
613	
614	Mathematical model
615	
616	For the single-country analyses presented in Figure 2, we assumed a population of 100
617	million and turnaround time of two weeks. We deterministically simulated variant and
618	wildtype epidemics, starting with one variant-infected individual, and computed the variant
619	proportion $f(t)$ through time. For each sequencing rate and given $f(t)$ , we computed the
620	expected day of detection with 95% confidence as the day on which the probability that zero
621	wildtype sequences would have been binomially sampled up to and including that day
622	declined below 0.05. On each day, the total number of samples to sequence was assumed to
623	be a Poisson-valued random variable with rate given by the sequencing rate. For each
624	sequencing rate, the day of detection was computed as the median across 100 replicates. To
625	compute the equivalent fold increase in sequencing rate for each reduction in turnaround
626	time, we computed the slope of a linear model that relates the logarithm of the sequencing
627	rate to the simulated day of detection for $1 < n < 100$ S/M/wk. In Extended Data Fig. 5 and 6

628 we show the analyses of time to detection for all combinations of variant  $R_e$  and scenario of 629 variant emergence (e.g. a variant with  $R_e = 2$  with wildtype dynamics corresponding to the 630 scenario for variant  $R_e = 1.2$  (wt  $R_e = 1$ , wt prevalence = 0.1%)).

631

632 To mathematically model time to variant detection, we assumed that the variant frequency

- 633 follows a logistic growth function, where the proportion f(t) of all new infections at time t
- that is attributable to the variant follows: 634

635 
$$f(t) = \frac{1}{1 + \frac{1 - f_0}{f_0} e^{-st}}$$

636 Here, s is the logistic growth rate that defines the speed at which the variant displaces the wildtype and  $f_0$  represents the initial variant frequency. The dynamics of logistic growth of 637 variant proportion characterized the sequential replacement of variants during the COVID-19 638 639 pandemic. Assuming no interactions between genotypes, the value of s is equal to the difference of variant and wildtype exponential growth rates<sup>23</sup>. In reality, s is governed by 640 factors such as pre-existing immunity in the population and differences in epidemiological 641 characteristics of variant and wildtype such as their generation interval. Nevertheless, the 642 643 derived relationship relies solely on the value of s, and hence is agnostic to the precise epidemiological characteristics of wildtype and variant. Given these dynamics, we derived a 644 relationship between the number of viruses to sequence per unit time *n* and the expected time 645 until the variant is detected. Beginning with the binomial probability that variant is detected 646 647 at or before time step  $\tau$ :

648 
$$P(t \le \tau) = 1 - \prod_{\tau}^{\tau} [1 - \tau]$$

$$P(t \le \tau) = 1 - \prod_{t=0}^{\tau} [1 - f(t)]^n$$

649 we derived an expression for  $\tau$ :

650 
$$\prod_{t=0}^{\tau} [1 - f(t)]^n = 1 - P(t \le \tau)$$
$$\ln[1 - P(t \le \tau)]$$

651 
$$n = \frac{\ln[1 - P(t \le \tau)]}{\ln\{\prod_{t=0}^{\tau}[1 - f(t)]\}}$$

652 Using the Volterra product integral:

653 
$$\prod_{a}^{b} [1+f(x)dx] = \exp\left(\int_{a}^{b} f(x) dx\right)$$
$$\ln[1-P(t \le \tau)] \qquad \ln[1-P(t \le \tau)]$$

654 
$$n = \frac{\ln[1 - P(t \le \tau)]}{\ln[\exp(\int_0^\tau - f(t) \, dt)]} = \frac{\ln[1 - P(t \le \tau)]}{-\int_0^\tau f(t) \, dt}$$

655 Integrating 
$$f(t)$$
:

656  
657  

$$F(t) = \int f(t) dt$$

$$= \int \frac{1}{1 + \frac{1 - f_0}{f_0} e^{-st}} dt$$

658 
$$= \int \frac{e^{st}}{e^{st} + \frac{1 - f_0}{f_0}} dt$$

660 
$$= \frac{1}{s} \int \frac{1}{e^{st} + \frac{1 - f_0}{f_0}} s e^{st} dt$$

659

661 
$$= \frac{1}{s} \ln \left| e^{st} + \frac{1 - f_0}{f_0} \right| + C$$

662 
$$= \frac{1}{s} \ln \left| \frac{f_0(e^{st} - 1) + 1}{f_0} \right| + C$$

663

664 
$$= \frac{1}{s} \ln|f_0(e^{st} - 1) + 1| - \frac{1}{s} \ln\left|\frac{1}{f_0}\right| + C$$

665 
$$= \frac{1}{s} \ln(f_0(e^{st} - 1) + 1)$$

666 We can then rewrite:

667 
$$n = \frac{\ln[1 - P(t \le \tau)]}{-F(\tau)}$$

668 
$$= \frac{s \cdot \ln[1 - P(t \le \tau)]}{-\ln(f_0(e^{s\tau} - 1) + 1)}$$

669 
$$\frac{n}{s} = \frac{\ln[1 - P(t \le t)]}{-\ln(f_0(e^{st} - 1) + 1)}$$

670

Let  $q = 1 - P(t \le \tau)$  which is the probability that the variant will *not* be detected before or 671 672 during time step  $\tau$ .

673 
$$\operatorname{Ln}(f_0(e^{s\tau} - 1) + 1) = -\frac{s\ln q}{n}$$

674 
$$f_0(e^{s\tau} - 1) + 1 = q^{-s/n}$$

676 
$$e^{s\tau} = \frac{q^{-s/n} - 1}{f_0} + 1$$

675 
$$\tau = \frac{\ln \frac{q^{-s/n} - 1}{f_0} + 1}{s} [Eq. 1]$$

677

678 This equation yields, given s, n,  $f_0$ , and q, the day  $\tau$  on which the variant will have been 679 detected at least once with confidence level 1 - q. This equation is valid when the timescales of detection are smaller than the timescales at which the logistic growth dynamics do not 680 681 hold. For example, in extreme scenarios of a very high wildtype  $R_{e}$ , a small variant 682 transmission advantage and a low sequencing rate, the timescale of variant detection is 683 beyond that of depletion of the susceptible population and the assumptions of the equation are not satisfied. We compared the predicted time to detection at 95% confidence for sequencing 684 685 rates *n* ranging from 0.1 to 1000 S/M/wk as computed using epidemic simulations (Fig. 2a in 686 main text) to predicted time to detection using only Eq. 1. In computing time to detection

687 using the equation, we used the empirical value of  $f_0$  from the epidemic simulations as input, with q = 0.05. We used the theoretical value of s, computed as (variant  $R_e$  - wildtype  $R_e$ ) / 5. 688 We performed this simulation for all four scenarios of variant emergence (each corresponding 689 to a different initial wildtype  $R_e$  and wildtype prevalence) and all four values of variant  $R_e$ . As 690 691 seen in Extended Data Fig. 4, there was high correspondence between the time to detection 692 from the explicit epidemic simulations and Eq. 1 when the variant  $R_e$  was high and/or 693 wildtype prevalence was low. In contrast, when variant  $R_e$  was low and wildtype prevalence 694 was high, susceptible depletion would occur before the timescale at which the variant would 695 be detected, and the time to detection as predicted using the equation would deviate from the 696 simulated time to detection. We note that, for combinations of initial variant proportion and 697 variant proportion logistic growth rate not explicitly discussed in this study, the mathematical 698 model can be used to compute the expected time to variant detection. 699

- 700 Variant prevalence estimation
- 701

702 In addition to variant detection, we investigated the relationship between sequencing rates 703 and the accuracy with which the spread dynamics of the variant can be tracked following its 704 detection. Specifically, we investigated the accuracy with which the weekly proportion of 705 new infections that is attributable to the variant can be estimated, and how this accuracy depends on sequencing rate. Mathematically, assuming a small, finite population N was 706 707 infected at prevalence  $\rho$  and samples were collected from fraction s of infected individuals 708 during each week, the potential (finite) number of samples that could be sampled from for 709 sequencing is *N* $\rho$ *s*.

710

711 Suppose the true circulating proportion is p and n (i.e.  $n < N\rho s$ ) number of samples were

- sequenced, the number of variant sequences (*X*) follows a hypergeometric distribution withmean and variance:
- 714

715

$$E(X) = np$$
$$Var(X) = np(1-p)\left(\frac{N\rho s - n}{N\rho s - 1}\right)$$

716 The variance of the variant proportion  $\hat{p} (= X/n)$  showing up in the sequences is:

717 
$$Var(\hat{p}) = \frac{p(1-p)}{n} \left( \frac{N\rho s - n}{N\rho s - 1} \right)$$

718 By Central Limit Theorem,  $\frac{\hat{p}-p}{\sqrt{\frac{p(1-p)}{n}(\frac{\rho s N-n}{\rho s N-1})}}$  follows an approximate Normal distribution.

As such, at 95% ( $\alpha = 5\%$ ) confidence, the error ( $\epsilon$ ) around the true variant proportion is:

720 
$$\epsilon = Z_{\alpha/2} \sqrt{\frac{p(1-p)}{n} \left(\frac{N\rho s - n}{N\rho s - 1}\right)}$$

For sequencing rate of *r* sequences per million persons per week (hence  $n = \frac{rN}{c}$  where  $c = 10^6$ ):

723 
$$\epsilon = Z_{\alpha/2} \sqrt{\frac{p(1-p)}{r} \left(\frac{c\rho s - r}{N\rho s - 1}\right)}$$

If  $N\rho s$  is sufficiently large (i.e.  $N\rho s \gg n = \frac{rN}{c} \rightarrow c\rho s \gg r$ ), 724

725 
$$\epsilon \to Z_{\alpha/2} \sqrt{\frac{p(1-p)}{r} \left(\frac{c}{N}\right)}$$

726 In Extended Data Fig. 9, we visualized the relationship between sequencing rate and the error 727 in the estimated variant proportion, for different population sizes, true variant proportions, 728 and values of  $\alpha$ .

729

731

730 Sensitivity analyses

732 In our analyses, we defined a sequence's turnaround time as the time between the sequence's 733 collection date and its submission date on GISAID. This represents the most accurate 734 measure of turnaround time available and has been used in previous analyses of global 735 sequencing output<sup>5</sup>. Nevertheless, a potential issue with this definition of turnaround time is a 736 lag between acquiring the sequence and its submission to GISAID, which is not reflected in these estimates<sup>28</sup>; in some cases, sequence analysis might have been performed but the 737 738 sequence would only later be deposited in GISAID. To establish the sensitivity of our global 739 simulation results to such delays in upload to GISAID, we re-simulated our global 740 metapopulation genomic surveillance simulations, where we assumed that the day the 741 sequence was acquired was somewhere between the sample's collection date and date of 742 submission to GISAID. Specifically, for each sequence, we computed the modified 743 turnaround time as  $\phi(t_{submission} - t_{collection})$ , for  $0 < \phi < 1$ . We re-simulated the genomic 744 surveillance simulation results as presented in Figure 3 for  $\phi = 0.25, 0.5$ . Varying  $\phi$  modifies 745 the (country-specific) turnaround time-specific sequencing rates used in the global genomic 746 surveillance system. Results for different values of  $\phi$  are presented in Extended Data Fig. 10a. For all values of  $\phi$  tested, we find that the conclusion holds that more solidaristic 747 748 strategies for the global distribution of respiratory virus surveillance infrastructure (strategies 749 A and C) offer strongly reduced time to variant detection. Hence, our results are robust to 750 biases resulting from deviations from the assumption that the submission date represents the 751 date on which the sample is available. Importantly, the observed consistency between a 752 country's sequencing rate and its median turnaround time (Spearman's  $\rho = -0.60$ ,  $P = 5.1 \times$ 753 10<sup>-21</sup>) suggests that a country's distribution of turnaround times as computed from GISAID 754 yields a representative picture of a country's true capacity to rapidly sequence a virus after 755 sample collection.

756 757

In our model, we estimated the mobility rate  $w_{nm}$  for countries m and n by dividing the number of trips from *m* to *n* in 2016 in the GTM by the population in *m*. This assumes that all 758 759 members of the population participate in disease-relevant spread. In reality, this will not be

- 760 the case. However, for the results of our study, these differences are likely to be of little
- consequence. Specifically, a lower effective mobility rate would further increase the 761

762 reduction in time to detection that would result from the establishment of minimum 763 sequencing infrastructure globally, as the time until a variant that emerges in a lowsequencing rate environment is exported to a high-sequencing rate environment would 764 765 increase. We explicitly investigated the potential effects of misspecification of the mobility 766 matrix on our results by multiplying and dividing the mobility rate matrix by three, 767 representing substantially increased and reduce spread, respectively (Extended Data Fig. 10b). A reduced rate would further increase the gains to be effected by the establishment of 768 769 sequencing infrastructure globally. Even if the mobility rate was increased three-fold, the 770 strategies with increased solidarity in the global distribution of genomic surveillance 771 infrastructure yield strongly improved performance compared to the 2022 baseline. Hence,

- 772 our results are robust to specifics of the mobility dynamics.
- 773

774 Our analyses wholly rely on GISAID data to inform the global landscape of respiratory virus 775 genomic surveillance infrastructure. In some countries, incomplete or absent deposition of 776 sequence data in GISAID may result in sequencing rates computed from GISAID data being 777 unreliable. For example, the zero-covid policy in China that was in place for parts of 2022, 778 combined with a relatively small number of sequences in GISAID, suggest that submission 779 rates to GISAID may not accurately represent China's true genomic surveillance capacity<sup>51</sup>. 780 We tested the possible implications of such biases on our results by comparing the results if 781 all epidemic simulations with new variant viruses originating in China were removed. When 782 China was removed from the set of possible epidemic origin locations, the conclusions 783 regarding the performance of the different strategies for the global distribution of genomic 784 surveillance infrastructure remained unchanged. The representativeness of GISAID data is 785 further supported by the extremely strong correlation between sequence output and GDP (Spearman's  $\rho = 0.79$ ,  $P = 6.3 \times 10^{-41}$ ). 786

787

### 788 **Data availability**

- 790 Data on global population sizes are available from the United Nations World Population
- 791 Prospects 2022 (https://population.un.org/wpp/Download/Standard/MostUsed/). Data on
- 792 country GDP (https://data.worldbank.org/indicator/NY.GDP.PCAP.CD) and income
- 793 classification (https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-
- 794 bank-country-and-lending-groups) is available from the World Bank. The Global
- 795 Transnational Mobility Dataset is available from the Global Mobilities Project
- 796 (https://migrationpolicycentre.eu/globalmobilities/dataset/). Metadata on global SARS-CoV-2
- 797 and seasonal influenza virus sequencing rates were extracted from GISAID
- 798 (www.gisaid.org). Raw global epidemic simulation output is available at
- 799 https://zenodo.org/records/10051237.
- 800
- 801 **Code availability**
- 802
- 803 Custom code and data used to generate the results in this study is publicly available at
- 804 https://github.com/AMC-LAEB/genomic surveillance solidarity.
- 805

807	References			
808	1			
809 810	1.	Viana, R. <i>et al.</i> Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. <i>Nature</i> <b>603</b> , 679–686 (2022).		
811 812	2.	Ladner, J. T. & Sahl, J. W. Towards a post-pandemic future for global pathogen genome sequencing <i>PLOS Biol</i> <b>21</b> e3002225 (2023)		
813	3.	Hill, V. <i>et al.</i> Toward a global virus genomic surveillance network. <i>Cell Host Microbe</i>		
814		<b>31</b> , 861–873 (2023).		
815 816	4. 5	World Health Organization (WHO). International Health Regulations. (2005).		
010 017	5.	Commun 12, 7002 (2022)		
01/ 010	6	<i>Commun.</i> 13, 7005 (2022).		
819	0.	Nature 579, 265–269 (2020).		
820	7.	Krammer, F. SARS-CoV-2 vaccines in development. Nature 586, 516–527 (2020).		
821 822	8.	null, null. Emergence of a Novel Swine-Origin Influenza A (H1N1) Virus in Humans.		
022	0	Wehl S. Les E. C. DiBrete D. L. & Lessler, I. Semula size calculations for nother son		
025 924	9.	wolli, S., Lee, E. C., Dirfele, B. L. & Lessier, J. Sample size calculations for pathogen		
825		Med. 4, (2023).		
826	10.	Hill, V., Ruis, C., Bajaj, S., Pybus, O. G. & Kraemer, M. U. G. Progress and		
827		challenges in virus genomic epidemiology. Trends Parasitol. 37, 1038–1049 (2021).		
828	11.	Méder, Z. Z. & Somogyi, R. Optimal capacity sharing for global genomic surveillance.		
829		<i>Epidemics</i> <b>43</b> , 100690 (2023).		
830	12.	Shu, Y. & McCauley, J. GISAID: Global initiative on sharing all influenza data - from		
831		vision to reality. Euro surveillance : bulletin Europeen sur les maladies transmissibles		
832		<i>= European communicable disease bulletin</i> vol. 22 at https://doi.org/10.2807/1560-		
833		7917.ES.2017.22.13.30494 (2017).		
834	13.	Balcan, D. et al. Seasonal transmission potential and activity peaks of the new		
835		influenza A(H1N1): a Monte Carlo likelihood analysis based on human mobility. BMC		
836		<i>Med.</i> <b>7</b> , 45 (2009).		
837	14.	Broeck, W. Van den et al. The GLEaMviz computational tool, a publicly available		
838		software to explore realistic epidemic spreading scenarios at the global scale. BMC		
839		Infect. Dis. 11, 37 (2011).		
840	15.	Sangiovanni, Andrea; Viehoff, J. Solidarity in Social and Political Philosophy. in The		
841		Stanford Encyclopedia of Philosophy (Summer 2023, Metaphysics Research Lab,		
842		Stanford University 2023).		
843	16.	Prainsack, Barbara; Buyx, A. Solidarity: Reflections on an Emerging Concept in		
844		Bioethics. Nuff. Counc. Bioeth. (2011).		
845	17.	Taylor, A. L. et al. Solidarity in the wake of COVID-19: reimagining the International		
846		Health Regulations. <i>Lancet</i> <b>396</b> , 82–83 (2020).		
847	18.	Toebes, B., Forman, L. & Bartolini, G. Toward Human Rights-Consistent Responses		
848		to Health Emergencies: What Is the Overlap between Core Right to Health		
849		Obligations and Core International Health Regulation Capacities? Health Hum. Rights		
850		<b>22</b> , 99–111 (2020).		
851	19.	Boyle, L. <i>et al.</i> Selective sweeps in SARS-CoV-2 variant competition. <i>Proc. Natl.</i>		
832 852	20	Actual Sci. 119, $e22158/9119$ (2022). Willingen E et al. A score of concernin compatible second labor the SADS C M 2		
855 854	20.	pandemic unfolded in Africa. <i>Science (80 ).</i> <b>374</b> , 423–431 (2021).		
855	21.	Tegally, H. <i>et al.</i> The evolving SARS-CoV-2 epidemic in Africa: Insights from rapidly		
856		expanding genomic surveillance. <i>Science (80 ).</i> <b>378</b> , eabq5358 (2023).		

medRxiv preprint doi: https://doi.org/10.1101/2023.11.01.23297901; this version posted November 27, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

857 22. Hill, V. et al. The origins and molecular evolution of SARS-CoV-2 lineage B.1.1.7 in the UK. Virus Evol. 8, veac080 (2022). 858 859 23. Davies, N. G. et al. Estimated transmissibility and impact of SARS-CoV-2 lineage 860 B.1.1.7 in England. Science (80-.). 372, eabg3055 (2021). 861 Anderson, A. S. A lightspeed approach to pandemic drug development. Nat. Med. 28, 24. 862 1538 (2022). 863 25. Newland, M. et al. Improving pandemic preparedness through better, faster influenza 864 vaccines. Expert Rev. Vaccines 20, 235-242 (2021). 865 26. Han, A. X. et al. SARS-CoV-2 diagnostic testing rates determine the sensitivity of 866 genomic surveillance programs. Nat. Genet. 55, 26-33 (2023). Salyer, S. J. et al. The first and second waves of the COVID-19 pandemic in Africa: a 867 27. 868 cross-sectional study. Lancet 397, 1265–1275 (2021). 869 28. Kalia, K., Saberwal, G. & Sharma, G. The lag in SARS-CoV-2 genome submissions to 870 GISAID. Nat. Biotechnol. 39, 1058–1060 (2021). 871 29. Sahadeo, N. S. D. et al. Implementation of genomic surveillance of SARS-CoV-2 in 872 the Caribbean: Lessons learned for sustainability in resource-limited settings. PLOS Glob. Public Heal. 3, e0001455 (2023). 873 874 Lavery, J. V. Porter, R. M. & Addiss, D. G. Cascading failures in COVID-19 vaccine 30. 875 equity. Science (80-. ). 380, 460-462 (2023). 876 31. Wouters, O. J. et al. Challenges in ensuring global access to COVID-19 vaccines: 877 production, affordability, allocation, and deployment. Lancet 397, 1023-1034 (2021). 878 Ortiz, J. R. & Neuzil, K. M. Influenza Immunization in Low- and Middle-Income 32. 879 Countries: Preparing for Next-Generation Influenza Vaccines. J. Infect. Dis. 219, S97-880 S106 (2019). 881 33. Moodley, K. et al. Ethics and governance challenges related to genomic data sharing in 882 southern Africa: the case of SARS-CoV-2. Lancet Glob. Heal. 10, e1855-e1859 883 (2022).884 34. Ramsay, M. African genomic data sharing and the struggle for equitable benefit. 885 Patterns 3, 100412 (2022). 886 Preiser, W., Engelbrecht, S. & Maponga, T. No point in travel bans if countries with 35. 887 poor surveillance are ignored. Lancet 399, 1224 (2022). 888 36. Carlson, C. et al. Save lives in the next pandemic: ensure vaccine equity now. Nature 889 626, 952-953 (2024). 890 Lancet, T. The Pandemic Treaty: shameful and unjust. Lancet 403, 781 (2024). 37. 891 38. Olawoye, I. B. et al. Emergence and spread of two SARS-CoV-2 variants of interest in 892 Nigeria. Nat. Commun. 14, 811 (2023). 893 39. Mashe, T. et al. Genomic epidemiology and the role of international and regional 894 travel in the SARS-CoV-2 epidemic in Zimbabwe: a retrospective study of routinely 895 collected surveillance data. Lancet Glob. Heal. 9, e1658-e1666 (2021). 896 40. Olono, A., Mitesser, V., Happi, A. & Happi, C. Building genomic capacity for 897 precision health in Africa. Nat. Med. (2024) doi:10.1038/s41591-024-03081-9. 898 41. Onywera, H. et al. Boosting pathogen genomics and bioinformatics workforce in 899 Africa. Lancet Infect. Dis. 24, e106-e112 (2024). 900 42. Omotoso, O. E. et al. Bridging the genomic data gap in Africa: implications for global 901 disease burdens. Global. Health 18, 103 (2022). West-Oram, P. G. N. & Buyx, A. Global Health Solidarity. Public Health Ethics 10, 902 43. 903 212-224 (2017). 904 44. Prainsack, B. & Buyx, A. Solidarity in Biomedicine and Beyond. Cambridge Bioethics 905 and Law (Cambridge University Press, 2017). doi:DOI: 10.1017/9781139696593. 906 45. James, Chris; Savedoff, W. Risk Pooling and Redistribution in Health Care: An

907		Analysis of Attitudes toward Solidarity. in World Health Report (2010) Background
908		paper No. 5 (2010).
909	46.	Genschel, Philipp; Hemerijck, A. Solidarity in Europe. in 01 EUI Policy Brief. (2018).
910	47.	Baute, S. & de Ruijter, A. EU health solidarity in times of crisis: explaining public
911		preferences towards EU risk pooling for medicines. J. Eur. Public Policy 29, 1183-
912		1205 (2022).
913	48.	Brockmann, D. & Helbing, D. The Hidden Geometry of Complex, Network-Driven
914		Contagion Phenomena. Science (80 ). 342, 1337–1342 (2013).
915	49.	Deutschmann, E., Recchi, E. & Vespe, M. Assessing Transnational Human Mobility
916		on a Global Scale BT - Migration Research in a Digitized World: Using Innovative
917		Technology to Tackle Methodological Challenges. in (eds. Pötzschke, S. & Rinken, S.)
918		169–192 (Springer International Publishing, 2022). doi:10.1007/978-3-031-01319-5_9.
919	50.	Klamser, P. P. et al. Inferring country-specific import risk of diseases from the world
920		air transportation network. arXiv e-prints arXiv:2304.12087 at
921		https://doi.org/10.48550/arXiv.2304.12087 (2023).
922	51.	Preiser, W. & Maponga, T. So far, no novel SARS-CoV-2 variants from
923		Beijing— and hopefully better scientific cooperation going forward. Lancet
924		<b>401</b> , 621–622 (2023).

medRxiv preprint doi: https://doi.org/10.1101/2023.11.01.23297901; this version posted November 27, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



926 927

#### 928 Extended Data Fig 1. The global distribution of sequencing output.

929 (A) The cumulative proportion of the global population that accounts for a cumulative

930 proportion of global sequence output for SARS-CoV-2. Data on sequencing output

corresponds to SARS-CoV-2 sequences in GISAID with collection date in 2022. Solid grev 931

lines show the smallest proportion of the population that accounts for 50% of sequencing 932

933 output. Dashed grey lines show the smallest proportion of sequencing output that is

accounted for by 50% of the global population. (B) The cumulative proportion of the global 934

935 population that accounts for a cumulative proportion of global seasonal influenza sequence

936 output. Data on sequencing output corresponds to seasonal influenza sequences collected

937 from humans in GISAID with collection date in 2018. Solid grey lines show the smallest

proportion of the population that accounts for 50% of sequencing output. Dashed grev lines 938

939 show the smallest proportion of sequencing output that is accounted for by 50% of the global 940 population.

941

942

944



945

946 Extended Data Fig. 2. Validation of the metapopulation model against GLEAM. For ten geographically representative countries, global variant spread was simulated, initialized in the 947

948 country's capital city, in GLEAM. For each of the 10 index countries, all global countries'

949 epidemic onset timings as simulated using GLEAM were compared against the countries'

epidemic onset timings as simulated using the epidemic model used in this study. For both 950

951 models, timings were computed as the median across 10 independent simulations.

952 Simulations are for a variant  $R_e$  of 1.6.

medRxiv preprint doi: https://doi.org/10.1101/2023.11.01.23297901; this version posted November 27, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



954 955

956 **Extended Data Fig. 3. Different scenarios of variant emergence.** For each of the values of 957 variant  $R_e$ , the corresponding panel shows the epidemiological dynamics of variant and 958 wildtype for that scenario of variant emergence, starting from the day of variant introduction. 959 For each value of variant  $R_e$ , the scenario of variant emergence is characterized by a different

960 value of wildtype  $R_e$  and wildtype prevalence at introduction.







962 963 Extended Data Fig. 4. Validation of derived time to variant detection. The red points show the relationship between time to detection simulated using binomial sampling (x-axis) 964 965 and time to detection computed using the derived mathematical model (y-axis). The dashed 966 grey line corresponds to y=x. Each panel corresponds to a different variant  $R_e$  and different scenario of variant emergence (i.e. a different value of wildtype  $R_e$  and wildtype prevalence 967 968 at time of variant introduction). This illustrates that the equation is valid, unless the 969 timescales of detection are smaller than the timescales at which the logistic growth dynamics 970 do not hold (bottom left quadrant), e.g. when susceptible depletion occurs before the variant

- 971 is expected to be detected (see Methods).
- 972
- 973
- 974







Extended Data Fig. 5. The dependence of time to variant detection on sequencing rate 978 for varying scenario of variant emergence. (A) Relationship between sequencing rate and 979 the number of days until the variant will have been detected with 95% confidence. The small 980 black tick marks on the x-axes in this plot and in **B** show country-specific SARS-CoV-2 sequencing rates for 2022. Each panel corresponds to a different scenario of variant 981 982 emergence, characterized by a wildtype (wt)  $R_e$  and wildtype prevalence at introduction. In 983 each panel, lines are colored by value of variant  $R_e$ . (B) Relationship between sequencing rate and the reduction in time to variant detection that results from increasing the existing 984 985 sequencing rate (x-axis) by 1 S/M/wk.

medRxiv preprint doi: https://doi.org/10.1101/2023.11.01.23297901; this version posted November 27, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



987

988 Extended Data Fig. 6. The dependence of the number of variant infections by day of 989 detection on sequencing rate for varying scenario of variant emergence. (A) Relationship 990 between sequencing rate and the number of infections by the day the variant will have been 991 detected with 95% confidence. The small black tick marks on the x-axes in this plot and in **B** 992 show country-specific SARS-CoV-2 sequencing rates for 2022. Each panel corresponds to a 993 different scenario of variant emergence, characterized by a wildtype (wt)  $R_e$  and wildtype 994 prevalence at introduction. In each panel, lines are colored by value of variant  $R_e$ . (B) 995 Relationship between sequencing rate and the reduction in the number of variant infections 996 by the day of variant detection that results from increasing the existing sequencing rate (x-

- 997 axis) by 1 S/M/wk.
- 998





1001 Extended Data Fig. 7. Time to global variant detection by strategy and scenario of

1002 variant emergence. (A) Time to global variant detection by strategy for the global

1003 distribution of respiratory virus surveillance infrastructure, by variant  $R_e$ , for varying scenario

1004 of variant emergence (characterized by wildtype (wt)  $R_e$  and wildtype prevalence (N = 10,000

1005 for each). Thin and thick lines correspond to 95% and 50% CIs, respectively. Points

correspond to means. (B) Number of global variant infections by the day of first detection by 1006 1007

strategy for the global distribution of respiratory virus surveillance infrastructure, by variant  $R_e$ , for varying scenario of variant emergence (characterized by wildtype (wt)  $R_e$  and wildtype 1008

1009 prevalence).



1010

Extended Data Fig. 8. Time to ascertainment of substantial variant proportion by 1011 1012 strategy and scenario of variant emergence. (A) Time until the variant was found to 1013 account for a substantial proportion of circulating virus in at least one country, by strategy for 1014 the global distribution of respiratory virus surveillance infrastructure, by variant  $R_e$ , for 1015 varying scenario of variant emergence (characterized by wildtype (wt)  $R_e$  and wildtype 1016 prevalence). Thin and thick lines correspond to 95% and 50% CIs, respectively. Points correspond to means. (B) Number of global variant infections by the day the variant was 1017 1018 found to account for a substantial proportion of circulating virus in at least one country, by 1019 strategy for the global distribution of respiratory virus surveillance infrastructure, by variant  $R_e$ , for varying scenario of variant emergence (characterized by wildtype (wt)  $R_e$  and wildtype 1020 1021 prevalence). 1022





1025 variant proportion. For each sequencing rate given on the x-axis, for varying true variant proportion and population size, the y-axis shows the maximum error in the estimated weekly 1026 1027 proportion of total infections attributable to the variant. This maximum error is presented for varying confidence (i.e. the y-axis represents the error that the error in the estimated variant 1028 1029 proportion relative to the true variant proportion will be smaller than n% of the time, for n1030 given by the confidence level).

1031

1023

1032

1033

1034

medRxiv preprint doi: https://doi.org/10.1101/2023.11.01.23297901; this version posted November 27, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



1036

1037 Extended Data Fig. 10. Sensitivity analyses for time to detection.

(A) Sensitivity analysis for time to GISAID submission. Time to global variant detection by 1038 1039 strategy for the global distribution of respiratory virus surveillance infrastructure, by variant 1040  $R_e$ , for varying scenario of variant emergence (characterized by wildtype (wt)  $R_e$  and wildtype prevalence). Thin and thick lines correspond to 95% and 50% CIs, respectively. Points 1041 correspond to means. Given a sequence in GISAID's computed turnaround time T, a 1042 1043 sequence's adjusted turnaround time  $\tilde{T}$  was equal to  $\phi T$ . These adjusted turnaround times 1044 were used to inform country-specific sequencing infrastructure in the global genomic 1045 surveillance simulations. (B) Sensitivity analysis for mobility rate. Time to global variant 1046 detection by strategy for the global distribution of respiratory virus surveillance 1047 infrastructure, by variant Re, for varying scenario of variant emergence (characterized by 1048 wildtype (wt) Re and wildtype prevalence). Thin and thick lines correspond to 95% and 50% 1049 CIs, respectively. Points correspond to means. Each row corresponds to a modified global

- 1050 mobility rate (top: baseline mobility rate multiplied by 3; bottom: baseline mobility rate
- 1051 divided by 3).